SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as heightened speculation around a potential buyout and unconfirmed M&A rumors drive significant after-hours volume and price volatility. Community members are actively debating the legitimacy of these reports, with long-term shareholders analyzing historical valuation metrics and potential takeover scenarios while others speculate on the motivations behind recent unusual trading patterns.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

The Veil community is rallying around the project's focus on digital privacy and decentralization, often citing its multi-algorithm mining and staking capabilities as key differentiators. Investors are actively discussing the potential for a privacy-focused market surge, frequently highlighting the project's long-term utility alongside established privacy coins.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is trending due to significant liquidity concerns following the restricted withdrawal access in its private credit funds, which has sparked investor anxiety over potential sector-wide fallout. The community is actively debating whether this represents an isolated incident or a broader 'canary in the coal mine' moment for private credit stability amidst rising default risks.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

Investors are closely monitoring YETH as the community debates its weekly distribution payouts versus the underlying volatility of Ethereum. While some traders leverage the fund for its income potential during range-bound market phases, others remain cautious due to concerns regarding NAV erosion and management performance.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is currently a focal point for intense debate, as investors weigh ongoing regulatory developments like the Clarity Act against sentiment that the project is facing a long-term decline. While some community members view the current price as a prime accumulation opportunity for the long term, others are actively pivoting toward Bitcoin or expressing frustration over what they perceive as stagnant institutional interest and stalled performance.

ARK ETF Trust - ARK Autonomous Technology & Robotics ETF

ARK Autonomous Technology & Robotics ETF

ARKQ is capturing investor attention as community members debate whether emerging robotics and 'embodied AI' infrastructure will take the tech sector's leadership baton this year. The ETF remains a focal point for discussion regarding portfolio rotation into automation themes, with sentiment driven by institutional buying activity and the sector's long-term growth potential.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

ChainLink is trending as investors debate its long-term infrastructure value versus recent price consolidation, with community sentiment split between frustration over sluggish performance and high conviction in its role as a backbone for real-world asset tokenization. Many are actively discussing potential catalysts like upcoming regulatory clarity and institutional partnerships that they believe will eventually drive a significant supply-side squeeze.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

Investors are closely watching the ARK Innovation ETF as it experiences sharp volatility, with community members expressing polarized views on Cathie Wood's aggressive buying and selling patterns amid broader market rotation out of high-beta growth stocks. The ongoing discourse highlights concerns over the fund's long-term performance and its heavy exposure to volatile tech and crypto-linked assets, leading to intense debates between those betting on an innovation-led rebound and those skeptical of the fund's strategy.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie Inc. is trending as investors weigh strong Q4 earnings, highlighted by robust sales growth in its immunology portfolio, against concerns over Humira's declining revenue and broader pharmaceutical sector volatility. The community is actively discussing the stock's long-term growth potential and M&A prospects, specifically focusing on the company's aggressive search for obesity drug assets to compete in the weight-loss market.

SLB Ltd. engages in the provision of energy technology. It operates through the following business segments: Digital, Reservoir Performance, Well Construction, Production Systems, and All Other. The Digital segment involves the combination of digital solutions and data products with its Asset Performance Solutions. The Reservoir Performance segment consists of technologies and services for productivity and performance optimization. The Well Construction segment includes the full portfolio of products and services for well placement and performance, drilling, and wellbore assurance. The Production Systems segment focuses on the development of technologies and provides services to production and recovery from subsurface reservoirs to the surface, into pipelines, and refineries. The company was founded by Conrad Schlumberger and Marcel Schlumberger in 1926 and is headquartered in Houston, TX.

SLB Ltd.

Schlumberger Ltd.

Schlumberger is trending as investors focus on its pivotal role in the potential revival of Venezuela's energy sector following recent geopolitical shifts. Community sentiment is mixed, with long-term holders emphasizing the company's critical technical expertise in oilfield services while short-term traders closely monitor price consolidation and volatility ahead of upcoming earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Coinbase, on Thursday, received conditional approval from the OCC to establish Coinbase National Trust Company.</li><li>The company said the trust charter is intended to bring federal regulatory oversight to Coinbase’s custody and market infrastructure services.</li><li>Conditional approval requires Coinbase to complete governance, staffing, and operational readiness steps before launch.</li></ul>Coinbase (COIN) announced on Thursday that it has received conditional approval from the Office of the Comptroller of the Currency (OCC) to charter Coinbase National Trust Company. With the approval, Coinbase joins Circle (CRCL), Ripple (XRP), and Paxos, which received conditional trust bank charters back in December.The company said that the approval does not signal a shift into traditional banking. “Coinbase is not becoming a commercial bank. We will not be taking retail deposits. We will not be engaging in fractional reserve banking,” it&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.coinbase.com/en-in/blog/coinbase-receives-conditional-occ-approval-building-the-future-of-finance">said</a> in a blog post. It explained that the trust charter is intended to formalize its custody and infrastructure operations under a unified federal framework.<a href="https://stocktwits.com/symbol/COIN">COIN’s stock</a> edged 0.72% lower in afternoon trade amid weakness in the broader markets, both cryptocurrency and equities. On Stocktwits, retail sentiment around the cryptocurrency exchange remained in ‘bearish’ territory over the past day.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_02_133038_png_30719e7580.webp" alt="Screenshot 2026-04-02 133038.png" width="1275" height="145"><figcaption>COIN retail sentiment and message volume on April 2 as of 1:30 p.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">What Conditional OCC Approval Means For Coinbase</h2>Conditional approval from the OCC means that a company’s application is acceptable in principle but still subject to additional requirements before it can begin operations.For Coinbase, this means completing several steps, including establishing a board, finalizing governance structures, and passing a pre-opening regulatory examination. Only after these conditions are met can Coinbase National Trust Company begin operating as a national trust bank.The debate over whether companies like Coinbase will be allowed to offer rewards on stablecoin deposits continues to unfold in Washington. Crypto firms are&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/new-clarity-act-stablecoin-rules-set-for-crypto-review-today-banks-next/cZ7xDkORI8K">reportedly</a> scheduled to review a new draft of the stablecoin yield proposal today in a close-door session on Thursday, followed by the banking industry on Friday.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-falls-below-67-after-oil-spikes-trump-iran-warning-rattles-risk-assets/cZ7xFXXRI8G">Bitcoin Falls Below $67,000 After Oil Spikes, Trump's Iran Warning Rattles Risk Assets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Monitors display Coinbase signage during the company's initial public offering (IPO) at the Nasdaq market site April 14, 2021 in New York City. 

Coinbase Joins Circle, Ripple, Paxos In US Crypto Trust Bank Cohort After OCC Conditional Approval 

Coinbase said it will not take retail deposits or operate as a commercial bank.

Cryptocurrency

Coinbase said it will not take retail deposits or operate as a commercial bank.


Zacks Investment Ideas feature highlights Ark Invest's, SK Telecom, NVIDIA, Nebius and Sandisk 

Ark Invest's, SK Telecom, NVIDIA, Nebius and Sandisk have been highlighted in this Investment Ideas article.


<ul class="summary-bullets"><li>The therapy also demonstrated encouraging efficacy with changes that resulted in improved laboratory markers for the disease and the resolution of anemia, the company said.&nbsp;</li><li>Beam is now looking to make an application seeking the U.S. Food and Drug Administration’s approval for the therapy as early as 2026 year-end.</li></ul>Shares of Beam Therapeutics (BEAM) rallied 3% after hours on Wednesday after the company said that its clinical trial evaluating ristoglogene autogetemcel for the treatment of sickle cell disease (SCD) with severe vaso-occlusive crises demonstrated encouraging efficacy.The company said that risto-cel, its investigational genetically modified cell therapy, demonstrated an acceptable safety profile and encouraging efficacy with changes that resulted in improved laboratory markers for the disease and the resolution of anemia. The data from the trial was published in the The New England Journal of Medicine.Sickle cell disease (SCD) is a group of inherited blood disorders caused by a genetic mutation leading to abnormal hemoglobin, which causes red blood cells to become rigid, sickle-shaped, and prone to breaking down. SCD with severe vaso-occlusive crises (VOC) involves sickle-shaped red blood cells blocking blood flow, causing intense, often bone-deep pain, ischemia, and organ damage.“Based on the totality of data generated to date from the BEACON study and the optimized treatment and manufacturing process, we believe risto-cel has the potential to be best-in-class. With an estimated 10,000 patients with SCD in the U.S. eligible for gene therapies, and significant demand expected as these treatments become more widely available, risto-cel is well positioned within this growing market,” said Amy Simon, chief medical officer of Beam.Beam is now looking to make an application seeking the U.S. Food and Drug Administration’s approval for the therapy as early as 2026 year-end. The FDA previously granted risto-cel orphan drug designation and Regenerative Medicine Advanced Therapy (RMAT) designation.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around BEAM stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume fell from high to normal levels.<a href="https://stocktwits.com/symbol/BEAM">BEAM stock</a> has gained 37% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-agpu-stock-rise-today/cZ7HyVtRIF0">Why Did AGPU Stock Rise 120% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Beam Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is BEAM Stock Edging Higher After Hours Today?

The company said that risto-cel, its investigational genetically modified cell therapy, demonstrated an acceptable safety profile in a trial. 

Equity

OpenAI & Anthropic Prove the AI Revolution is Just Starting

While geopolitical tensions provide a constant drumbeat of anxiety for the average investor, the underlying fundamentals of the AI sector tell a much different story. 

<ul class="summary-bullets"><li>OpenAI on Tuesday announced that it raised $122 billion in equity financing – the largest investment round for any company.</li><li>The financing and stake sale of individual investors comes ahead of a potential initial public offerings, expected towards the end of the year.</li><li>Investors are increasingly eying exposure to marquee pre-IPO tech companies such as SpaceX and Anthropic, investing into funds that own them.</li></ul>Noted tech investor Cathie Wood has poured in $240 million as part of OpenAI’s mammoth $122 billion funding round – a significant development that opens the door for retail investors to gain exposure to the world’s leading AI company, which is also gearing up for an initial public offering.The investment is made from her three exchange traded funds ARK Innovation (ARKK), ARK Fintech Innovation (ARKF) and ARK Next Generation Internet (ARKW), according to ARK Invest disclosures.&nbsp;As a percentage of their total holdings, the OpenAI stake accounts for 3.1% for ARKK, and 3.0% for ARKW and ARKF. Wood had earlier invested a similar amount in OpenAI through her venture fund, the ARK Venture Fund.Separately, OpenAI said it secured over $3 billion investment as part of the round from individual investors – a first for the company.&nbsp;OpenAI is “broadening ownership and giving more people the opportunity to share in the upside economics of OpenAI and the AI era,” it said in the&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://openai.com/index/accelerating-the-next-phase-ai/">blog post</a> announcing its fundraise on Tuesday.Although the ARK ETFs have declined in the recent months, with ARK Innovation ETF (ARKK) logged its worst quarter since early 2025, the OpenAI stake might increase their appeal.Investors are increasingly seeking exposure to marquee pre-IPO tech companies such as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/how-to-buy-spacex-before-ipo-5-funds-owning-spacex/cZ3uVbqRIlL">SpaceX</a> and&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anthropic-s-ipo-said-to-be-coming-as-early-as-october-here-s-how-to-pick-up-a-stake-before-it-goes-public/cZ3uU4aRIlA">Anthropic</a>, and are investing in funds that own them, Stocktwits has reported.&nbsp;Besides the ARK ETFs, KraneShares Artificial Intelligence &amp; Technology ETF (AGIX), Fundrise Innovation Fund (VCX), and Destiny Tech100 (DXYZ) are some of the funds that have seen significant interest among retail traders on Stocktwits of late.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nike-stock-tumbles-toward-9-year-low-retail-traders-shrug-off-soft-outlook/cZ7HhpHRInK">Nike Stock Tumbles Toward 9-Year Low: Retail Traders Shrug Off Soft Outlook To Scoop Up ‘Crazy Good Pricing’</a>

Cathie Wood, CEO & Chief Investment Officer of ARK Invest, speaks onstage during Day 2 of 2023 Invest Fest at Georgia World Congress Center on August 27, 2023 in Atlanta, Georgia. (Photo by Paras Griffin/Getty Images)

Cathie Wood Makes $240M Bet In OpenAI's Mammoth Fundraise As IPO Looms

OpenAI said it is broadening access to its equity to public investors through the ARK ETFs – and also separately raised $3 billion from individual investors.

Cathie Wood, Founder & CEO, Ark Invest, speaks during the second day of the FII PRIORITY Summit held at the Faena Hotel on February 20, 2025 in Miami Beach, Florida. (Photo by Joe Raedle/Getty Images)

Cathie Wood’s Flagship Ark Fund Just Logged Its Worst Quarter In Over A Year — One Mega-Cap Stock Is Largely To Blame

Since early 2025, Tesla has shifted focus from EVs toward robotaxis, Full Self-Driving (FSD) rollout, Cybercab production, and AI-driven robotics.

<ul class="summary-bullets"><li>Bitmine has completed over 78% of its goal to acquire 5% of Ethereum’s total supply.</li><li>The company added around 71,179 ETH in the past week, bringing total holdings to around 4.7 million ETH.</li><li>Chairman Tom Lee said the crypto market is nearing the end of a “mini-crypto winter” and highlighted oil prices as a key driver.</li></ul>Shares of Bitmine Immersion Technologies (BMNR) rose nearly 5% in pre-market trade on Monday after the company announced that its treasury now holds 3.92% of Ethereum’s (ETH) overall token supply.Bitmine Chairman Tom Lee&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bmnr-stock-gains-after-bitmine-biggest-ethereum-buy-this-year/cZ3mfarRI0L">reiterated</a> that the crypto market is at the tail-end of the current “mini-crypto winter” and that tokens are a “good wartime store of value.”&nbsp;"The inverse correlation of crypto (and equities) to oil has been increasing and is at the highest levels in the past year. This is logical,” he said. “Until equity markets become comfortable with the future trajectory of oil prices, rising oil is a headwind for equities and crypto. And in a sense, the crypto winter likely ends when the upside risk to oil prices peaks.”The company said it has now completed over 78% of its goal of acquiring 5% of Ethereum’s circulating supply. Bitmine has continued its trend of increasing ETH purchases week-on-week, accumulating around 71,179 ETH in the past week, bringing its total to around 4.7 million ETH.<h2 class="st-heading-2">BMNR Stock Rises, Ethereum Recaptures $2,000</h2>Shares of Bitmine rose alongside Ethereum as it reclaimed the $2,000 mark on Monday morning amid a&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-recovers-from-65-000-analysts-warn-rally-may-be-short-lived/cZERZEoRIZp">broader rally</a> in the cryptocurrency market.&nbsp;<a href="https://stocktwits.com/symbol/BMNR/">BMNR’s stock</a> rose 4.3% in early morning trade, while retail sentiment on Stocktwits around the company fell to ‘neutral’ from ‘bullish’ territory over the past day, and chatter remained at ‘low’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_30_093808_png_c18a6a665e.webp" alt="Screenshot 2026-03-30 093808.png" width="1235" height="142"><figcaption>BMNR retail sentiment and message volume on March 30 as of 9:20 a.m. ET | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/coins/ethereum">Ethereum’s price</a> also rose around 4.3% in the last 24 hours to around $2,070. Retail sentiment around the leading altcoin on Stocktwits remained in ‘bearish’ territory amid ‘normal’ levels of chatter.Bitmine said its balance sheet is now worth $10.7 billion, which includes 197 Bitcoin (BTC), a $200 million stake in Beast Industries, a $102 million stake in Eightco Holdings (ORBS), and total cash of $961 million, in addition to its Ethereum holdings.&nbsp;Last week, the company also&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/tom-lee-says-mavan-will-be-largest-ethereum-staking-platform/cZ3YpSZRIS1">announced</a> the launch of its Made in America Validator Network (MAVAN) with Lee stating that it will be the “largest Ethereum staking network in the world.”Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-recovers-from-65-000-analysts-warn-rally-may-be-short-lived/cZERZEoRIZp">Bitcoin Recovers From $65,000 – Analysts Warn Rally May Be Short-Lived</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BMNR’s Tom Lee Says Crypto Winter May End When Oil Risk Peaks – Bitmine Adds Over 70,000 ETH To Holdings

Bitmine Immersion Technologies’ Ethereum holdings now total over 4.7 million ETH, amounting to nearly 4% of the altcoin’s supply.

The Zacks Analyst Blog Highlights FWD, ARKK, CHAT, AIQ and VOO

ARK Innovation ETF and peers offer exposure to AI-driven disruption, as investors are urged to stay invested despite market volatility and geopolitical risks.

<ul class="summary-bullets"><li>Cathie Wood’s ARK Investment Management bought more Tempus shares this week, even as the stock hit a one-year low and the firm trimmed exposure across several large tech holdings.</li><li>So far this year, ARKK and ARKG have poured nearly $28 million into Tempus shares.</li><li>The buying followed expanding AI-driven oncology partnerships with Daiichi Sankyo, Merck, Blood Cancer United, NYU Langone Health and Northwestern Medicine.</li></ul>Shares of Tempus AI Inc. (TEM) drew renewed attention this week after Cathie Wood’s ARK Investment Management added to its position while cutting stakes across several large tech firms, signaling continued conviction even as the stock hit a one-year low.<a href="https://stocktwits.com/symbol/TEM">TEM stock</a> fell nearly 3% on Thursday and is headed for its fifth straight weekly loss, shedding roughly 25% over the past five weeks.<h2 class="st-heading-2">Tempus Only Stock ARKK Bought In Latest Buy</h2>On Thursday, ARK Investment Management purchased 51,881 shares through the ARK Innovation ETF (ARKK), worth $2.4 million based on Tempus’ closing price of $45.53. Notably, Tempus was the only stock ARKK bought in the session, even as the firm reduced exposure across several large tech holdings, including Alphabet, Baidu, Broadcom, Illumina, Archer Aviation, AMD, Nvidia and Meta.The purchase followed additional accumulation a day earlier, when ARKK acquired 72,290 shares and the ARK Genomic Revolution ETF (ARKG) added 12,649 shares, worth $4 million.Earlier in the quarter, ARK accumulated shares following Tempus’ earnings report and momentum from its partnerships. On Feb.25, ARKK bought 179,013 shares, while ARKG added 33,812 shares, implying purchases worth about $11.4 million.The accumulation this year began on Feb.12, when ARKK purchased 174,585 shares and ARKG added 35,716 shares, representing roughly $10.7 million using Tempus’ $50.78 closing price. Cumulatively, ARK poured nearly $28 million into Tempus shares so far this year.<h2 class="st-heading-2">Tempus Expands Big Pharma AI Deals</h2>ARK’s accumulation comes after Tempus expanded its role in precision oncology research and clinical-trial optimization pipelines. Most recently, Tempus partnered with Japanese pharma giant Daiichi Sankyo to develop a new cancer therapy, using its Prism2 AI model to better identify patients most likely to benefit from treatment.Earlier this month, the company expanded its collaboration with Merck to support biomarker discovery across oncology and potentially broader therapeutic programs using its Lens platform and real-world datasets. Tempus also announced a deal with Blood Cancer United to build a registry focused on pediatric acute myeloid leukemia (AML).The developments followed additional collaborations this year with Median Technologies, NYU Langone Health and Northwestern Medicine supporting genomic testing workflows, lung-cancer screening and molecular oncology programs.<h2 class="st-heading-2">Wall Street Sees Long-Term Upside For Tempus</h2>Wall Street commentary this year reflected some price-target resets following quarterly results, but maintained confidence in Tempus’ long-term platform strategy. H.C. Wainwright raised its target to $95 and maintained a 'Buy' rating, while Baird lifted its target to $68 and reiterated an 'Outperform' rating. BTIG also maintained a 'Buy' rating, citing Tempus’s “first mover advantage on its large data business” and $1.1 billion backlog supporting expansion.Meanwhile, JPMorgan lowered its price target to $60 and kept a 'Neutral' rating, citing “clouded visibility” around data-segment upside, while TD Cowen cut its target to $70 and maintained a 'Hold' rating. Mizuho initiated coverage with an 'Outperform' rating and a $100 target, calling precision oncology diagnostics a $40 billion market growing about 30% annually.Tempus reported fourth-quarter revenue of $367.2 million, beating estimates, and projected fiscal-year 2026 revenue of about $1.59 billion, roughly in line with forecasts. CEO Eric Lefkofsky said that growth in diagnostics volumes and the company’s AI-driven data platform is expected to support expansion in the coming years.<h2 class="st-heading-2">What Do Retail Traders Feel About Tempus AI?</h2>On Stocktwits, retail sentiment for TEM has been in the ‘bearish’ territory over the past week, slipping from ‘extremely bullish’ levels a month ago amid over a 90% surge in message volumes this quarter. Meanwhile, the stock has seen nearly a 50% jump in watchers over the past year.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/tem_ss_png_ca8662c8d0.webp" alt="tem ss.png" width="978" height="143"><figcaption>TSLA sentiment and message volume as of March 27 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/GoAt2OG/message/648701463">expressed</a> optimism, noting that “The only thing Cathie bought today was us here at Tempus.”<stembedurl>https://stocktwits.com/GoAt2OG/message/648701463</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/MihaiGG/message/648612357">said</a>, “Experience told me that this is a good moment to buy, with what we can or what we have. Cathie is loading up, so, [why] don’t we? It will boom, someday, but success needs pain.”<stembedurl>https://stocktwits.com/MihaiGG/message/648612357</stembedurl>TEM stock has declined 15% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-misses-gas-price-tailwind-ahead-of-q1-delivery-report/cZ3uFS9RIli">Tesla Stock Fails To Catch Tailwind From Surging Gas Prices Ahead Of Crucial Q1 Delivery Report</a>

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Tempus AI Stock Near 1-Year Low: Cathie Wood’s ARK Buys More While Offloading Nvidia, Meta, Other Tech Plays

Tempus AI was the only stock purchased by ARK Innovation ETF (ARKK) in the latest session, signaling targeted conviction.

Stay Invested Despite Market Chaos With These ETFs

Stay invested amid market chaos. AI disruption and geopolitics may drive volatility, but these ETFs offer long-term growth and stability.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

ARKK
ARK Innovation ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ARKK News

ARKKARK Innovation ETF